Rovin Capital UT ADV Sells 2,256 Shares of Gilead Sciences, Inc. $GILD

Rovin Capital UT ADV lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 54.0% during the second quarter, according to its most recent filing with the SEC. The firm owned 1,925 shares of the biopharmaceutical company’s stock after selling 2,256 shares during the period. Rovin Capital UT ADV’s holdings in Gilead Sciences were worth $213,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Vestmark Advisory Solutions Inc. bought a new position in Gilead Sciences during the second quarter worth $214,000. Aspect Partners LLC grew its holdings in Gilead Sciences by 94.0% during the 2nd quarter. Aspect Partners LLC now owns 322 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 156 shares during the period. Walkner Condon Financial Advisors LLC raised its position in shares of Gilead Sciences by 3.0% in the 2nd quarter. Walkner Condon Financial Advisors LLC now owns 3,586 shares of the biopharmaceutical company’s stock worth $398,000 after acquiring an additional 103 shares in the last quarter. Bryn Mawr Trust Advisors LLC lifted its stake in shares of Gilead Sciences by 6.6% in the 2nd quarter. Bryn Mawr Trust Advisors LLC now owns 2,880 shares of the biopharmaceutical company’s stock valued at $319,000 after purchasing an additional 178 shares during the period. Finally, Savant Capital LLC boosted its position in shares of Gilead Sciences by 67.5% during the 2nd quarter. Savant Capital LLC now owns 49,086 shares of the biopharmaceutical company’s stock valued at $5,442,000 after purchasing an additional 19,777 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the sale, the chief financial officer directly owned 157,055 shares in the company, valued at $18,545,054.40. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total value of $1,193,900.00. Following the completion of the transaction, the chief executive officer owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 71,500 shares of company stock valued at $8,336,040 in the last quarter. Insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

GILD has been the subject of a number of research analyst reports. UBS Group lifted their target price on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a report on Friday, August 8th. BMO Capital Markets lifted their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a report on Monday, October 20th. The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $108.00 to $110.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. Morgan Stanley increased their target price on shares of Gilead Sciences from $143.00 to $147.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Finally, Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $127.82.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $118.84 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $86.08 and a fifty-two week high of $124.61. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The stock has a market cap of $147.46 billion, a P/E ratio of 23.67, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. The firm’s fifty day moving average price is $116.49 and its 200-day moving average price is $112.17.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s dividend payout ratio is currently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.